First Two Years’ Response to Growth Hormone Treatment in Very Young Preterm Small for Gestational Age Children

Background: Growth hormone (GH) is a therapeutic option for small for gestational age (SGA) children without spontaneous catch-up. There are few reports on preterm SGA children. Prematurity is an additional risk factor for adult short stature. Aim: To describe GH efficacy in preterm SGA patients. Methods: Twenty-five preterm SGA patients, 2–4 years old, treated with GH 0.066 mg/kg/day, were compared with 14 age-matched preterm SGA historical controls. Height, weight, IGF-I, IGFBP-3, fasting glucose and insulin were measured every 6 months. Results: At start of GH treatment, mean height and weight were –2.4 and –2.4 SDS, respectively. There was a significant increment in height SDS of 1.3 and 2.1 during the 1st and the 2nd year of GH therapy, respectively. There was no significant difference between the progression of chronological and bone ages. A significant increase in IGF-I, IGFBP-3 and molar ratio was observed during GH therapy. There was no difference in glucose, insulin or HOMA-IR index. Conclusion: We showed for the first time that the height increment of preterm SGA with GH treatment is similar to that described in other studies with term SGA patients. Therefore, short-term GH treatment in a subset of preterm SGA patients between 2–4 years of age was able to promote adequate growth recovery with no excessive bone age acceleration or adverse effects on carbohydrate metabolism.

[1]  F. Baş,et al.  Insulin resistance and body composition in preterm born children during prepubertal ages , 2008, Clinical endocrinology.

[2]  L. Ibáñez,et al.  Improvement in growth after two years of growth hormone therapy in very young children born small for gestational age and without spontaneous catch-up growth: results of a multicenter, controlled, randomized, open clinical trial. , 2007, The Journal of clinical endocrinology and metabolism.

[3]  P. Czernichow,et al.  Small for gestational age: short stature and beyond. , 2007, Endocrine reviews.

[4]  P. Czernichow,et al.  CONSENSUS STATEMENT: Management of the Child Born Small for Gestational Age through to Adulthood: A Consensus Statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society , 2007 .

[5]  F. Dekker,et al.  Long-term Height Gain of Prematurely Born Children With Neonatal Growth Restraint: Parallellism With the Growth Pattern of Short Children Born Small for Gestational Age , 2006, Pediatrics.

[6]  P. Saenger,et al.  Safety of Growth Hormone Treatment in Children Born Small for Gestational Age: The US Trial and KIGS Analysis , 2006, Hormone Research in Paediatrics.

[7]  F. de Zegher,et al.  Preterm Growth Restraint: A Paradigm That Unifies Intrauterine Growth Retardation and Preterm Extrauterine Growth Retardation and Has Implications for the Small-for-Gestational-Age Indication in Growth Hormone Therapy , 2006, Pediatrics.

[8]  D. Dunger,et al.  Growth Hormone Therapy in Short Children Born Small for Gestational Age , 2006, Hormone Research in Paediatrics.

[9]  S. Kurtoğlu,et al.  Homeostasis Model Assessment Is More Reliable Than the Fasting Glucose/Insulin Ratio and Quantitative Insulin Sensitivity Check Index for Assessing Insulin Resistance Among Obese Children and Adolescents , 2005, Pediatrics.

[10]  S. Chernausek.  Growth Hormone Treatment of Short Children Born Small for Gestational Age: A US Perspective , 2004, Hormone Research in Paediatrics.

[11]  A. Hokken-Koelega,et al.  Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. , 2003, The Journal of clinical endocrinology and metabolism.

[12]  P. Saenger.  US Experience in Evaluation and Diagnosis of GH Therapy of Intrauterine Growth Retardation/Small-for-Gestational-Age Children , 2002, Hormone Research in Paediatrics.

[13]  D L Streiner,et al.  Physical growth and current health status of infants who were of extremely low birth weight and controls at adolescence. , 2001, Pediatrics.

[14]  A. Hokken-Koelega,et al.  Carbohydrate metabolism during long‐term growth hormone treatment in children with short stature born small for gestational age , 2001, Clinical endocrinology.

[15]  D. Matthews,et al.  Lipid profile, glucose tolerance and insulin sensitivity after more than four years of growth hormone therapy in non‐growth hormone deficient adolescents , 1999, Clinical endocrinology.

[16]  F. de Zegher,et al.  Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. , 1999, The Journal of clinical endocrinology and metabolism.

[17]  L. Ibáñez,et al.  Growth Hormone Treatment of Short Children Born Small for Gestational Age , 1998, Trends in Endocrinology & Metabolism.

[18]  P. Czernichow,et al.  Growth Hormone in the Treatment of Short Stature in Young Children with Intrauterine Growth Retardation , 1998, Hormone Research in Paediatrics.

[19]  J. Graham,et al.  Evaluation of neonates born with intrauterine growth retardation: review and practice guidelines. , 1998, Journal of perinatology : official journal of the California Perinatal Association.

[20]  K. Albertsson-Wikland,et al.  Postnatal growth of children born small for gestational age , 1997, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[21]  T J Cole,et al.  Cross sectional stature and weight reference curves for the UK, 1990. , 1995, Archives of disease in childhood.

[22]  J. Dobbing,et al.  Fetal nutrition and cardiovascular disease in adult life , 1993, The Lancet.

[23]  J. Khoury,et al.  New Ballard Score, expanded to include extremely premature infants. , 1991, The Journal of pediatrics.

[24]  P. Bougnères,et al.  High‐Dose Growth Hormone Treatment of Non‐Growth Hormone‐Deficient Children: Preliminary Results after 2 Years , 1990, Acta paediatrica Scandinavica. Supplement.

[25]  D. Dunger,et al.  High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity. , 2002, The Journal of clinical endocrinology and metabolism.

[26]  P. Czernichow,et al.  Syndrome X: a consequence of intra-uterine malnutrition? , 2000, Journal of pediatric endocrinology & metabolism : JPEM.

[27]  A. Hokken-Koelega,et al.  Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. , 1999, The Journal of clinical endocrinology and metabolism.

[28]  D. Leon,et al.  Fetal growth and adult disease. , 1998, European journal of clinical nutrition.

[29]  F. de Zegher,et al.  Growth hormone treatment induces a dose-dependent catch-up growth in short children born small for gestational age: a summary of four clinical trials. , 1997, Hormone research.

[30]  G. Putet,et al.  Functional hypersomatotropism in small for gestational age (SGA) newborn infants. , 1989, The Journal of clinical endocrinology and metabolism.